Dialectic Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Dialectic Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-25,000	Closed	-$61K	–	57
2016 Q4	$61K	Buy	+25,000	New	+$72.7K	0.03%	76
2016 Q3	–	Sell	-25,000	Closed	-$87K	–	84
2016 Q2	$87K	Sell	25,000 -174,895	-87%	-$740K	0.03%	97
2016 Q1	$825K	Buy	+199,895	New	+$714K	0.39%	69

Other funds holding ABUS

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Dialectic Capital Management's ABUS Position: Q1 2017 in Review

Dialectic Capital Management sold out of Arbutus Biopharma (ABUS) in Q1 2017, closing a stake of 25,000 shares — an estimated $61K sold.

Dialectic Capital Management first reported a position in ABUS in Q1 2016 and held it in 3 quarters. The position peaked at $825K in Q1 2016. 53 funds tracked by Wall St. Rank hold ABUS as of Q1 2017.

Dialectic Capital Management reported no remaining Arbutus Biopharma position as of Q1 2017 after selling out during the quarter.
Dialectic Capital Management sold 25,000 Arbutus Biopharma shares in Q1 2017, an estimated $61K.
Dialectic Capital Management first reported a position in Arbutus Biopharma in Q1 2016 and held it in 3 quarters.
Dialectic Capital Management's Arbutus Biopharma position peaked at $825K in Q1 2016.
53 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2017.

Based on Dialectic Capital Management's 13F filing for Q1 2017, filed 11 May 2017.